Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Mirum Pharmaceuticals (MIRM) Change in Intangibles (2023 - 2024)

Mirum Pharmaceuticals has reported Change in Intangibles over the past 2 years, most recently at $10.0 million for Q3 2024.

Quarterly results put Change in Intangibles at $10.0 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Dec 2025 was $10.0 million (down 50.0% YoY), and the annual figure for FY2024 was $20.0 million, changed 0.0%.
Change in Intangibles for Q3 2024 was $10.0 million at Mirum Pharmaceuticals, roughly flat from $10.0 million in the prior quarter.
Over the last five years, Change in Intangibles for MIRM hit a ceiling of $15.0 million in Q1 2023 and a floor of $5.0 million in Q4 2023.